ShiraTronics

🌍 We’re honored to be recognized in BioSpectrum Asia’s “MedTech Disruption 2025: Startups Powering the Next Healthcare Leap” as a top startup to watch in advanced neuromodulation.

🔬 As we advance pivotal trials for our investigational, drug-free Migraine Therapy System, this acknowledgment highlights the urgent need for innovative solutions for people living with chronic migraine.

🎯 At ShiraTronics, our focus is clear: bring forward new science, restore quality of life, and offer hope where conventional therapies have fallen short.

https://www.biospectrumasia.com/opinion/27/26130/medtech-disruption-2025-startups-powering-the-next-healthcare-leap.html

Caution: Investigational device. Limited by Federal (or United States) law to investigational use.

What an incredible way to close out in Boston!

We were honored to see our RELIEV-CM clinical study data presented by Dr. Steven Falowski to a standing room only audience. It’s a powerful reflection of the growing momentum behind innovative solutions for chronic migraine — and a testament to the dedication of our entire ShiraTronics team and clinical collaborators.

A huge thank you to everyone who attended the session, engaged with the data, and shared in the excitement around advancing neuromodulation as a new frontier for migraine care.

The future is bright — and we’re just getting started!